Company: LHI
Filing Date: 2025-11-20
Form Type: F-1/A
Source: 0001213900-25-112807
Chunk: 6

Company: Living Homeopathy International Ltd.
Filing Date: 2025-11-20
Form: F-1/A
Chunk 6
---
 such issuer shall fulfill the CSRC filing procedure prior to its listing
on the foreign stock markets: (i) 50% or more of any of the issuer’s operating revenue, total profit, total assets or net assets
as documented in its audited consolidated financial statements for the most recent fiscal year is accounted for by mainland China companies;
and (ii) the main parts of the issuer’s business activities are conducted in mainland China, or its main place(s) of business are
located in mainland China, or the majority of senior management staff in charge of its business operations and management are PRC citizens
or have their usual place(s) of residence located in mainland China. Subject to final determination by the CSRC and relevant competent
authorities, Han Kun Law Offices, our PRC counsel, has advised us that, based on the facts that (i) we do not operate any entities in
mainland China and the revenue, total profit, total assets or net assets as documented in our audited consolidated financial statements
for the most recent fiscal year is accounted for by our Hong Kong subsidiary located outside mainland China; (ii) except for the operation
of our virtual flagship store on Tmall Global, an e-commerce platform for international businesses to directly sell our brand-name goods
to consumers in mainland China, which was recently set up in June 2024 and has not generated sales to consumers in mainland China, as
of the date of this prospectus, our business operations are conducted in Hong Kong; and (iii) our senior management team are not PRC
citizens and have their residence located outside mainland China, we do not meet the criteria as set forth in Article 15 of the
Overseas Listing Trial Measures, and are not required to fulfill the filing procedures with the CSRC to list our securities on a U.S.
securities exchange or issue securities to foreign investors. However, as the Overseas Listing Trial Measures were newly published, there
are substantial uncertainties that the CSRC may take a view that is contrary to our understanding of the Overseas Listing Trial Measures
because the CSRC may have substantial discretion over the determination of “indirect overseas offering and listing by a domestic
company.” Han Kun Law Offices LLP, our Hong Kong counsel, has advised us that, as of the date of this prospectus, Living Homeopathy
is not required to obtain any permission or approval from the governmental authorities of Hong Kong to list on the U.S. exchanges and
offer securities.

Nevertheless, if we